Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis

被引：0
|
作者：
Daungsupawong, Hinpetch [1 ]
Wiwanitkit, Viroj [1 ]
机构：
[1] Chandigarh Univ Gharuan, Univ Ctr Res & Dev, Dept Pharmaceut Sci, Mohali, Punjab, India
来源：
INFLAMMATORY BOWEL DISEASES | 2025年
关键词：
D O I：
10.1093/ibd/izae315
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis
    Kochhar, Gursimran S.
    Khataniar, Himsikhar
    Hashash, Jana G.
    Tabaku, Fjona
    Regueiro, Miguel
    Farraye, Francis A.
    Desai, Aakash
    INFLAMMATORY BOWEL DISEASES, 2024,
  • [2] Comparative Effectiveness of Ozanimod and Vedolizumab as First-Line Advanced Therapies in Ulcerative Colitis: A Propensity-Matched Cohort Analysis
    Kochhar, Gursimran S.
    Khataniar, Himsikhar
    Hashash, Jana G.
    Farraye, Francis A.
    Desai, Aakash
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S780 - S781
  • [3] Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis
    Kakiuchi, Toshihiko
    Yoshiura, Masato
    CLINICAL THERAPEUTICS, 2022, 44 (07) : 1028 - 1032
  • [4] Ulcerative Colitis Therapy: Vedolizumab as a First-line Biologic Agent?
    Metzger, Leandra
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (03): : 274 - 276
  • [5] Real World Experience With Vedolizumab as First-Line Therapy for the Treatment of Ulcerative Colitis
    Ritter, Timothy E.
    Mehta, Samantha A.
    Van Anglen, Lucinda J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S439 - S439
  • [6] Comparative Effectiveness of First-Line Infliximab and Vedolizumab in Patients with Early Ulcerative Colitis
    Hemed, A. Rozenfeld
    Cohen, N. A.
    Green, O.
    Hirsch, A.
    Thurm, T.
    Ron, Y.
    Fishman, S.
    Leibovitzh, H.
    Maharshak, N.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1476 - I1477
  • [7] Rates of Treatment Failure Among Patients With Ulcerative Colitis Treated With First-Line Advanced Therapies
    Lee, Scott D.
    LaPensee, Kenneth
    Betts, Keith A.
    Du, Ella Xiaoyan
    Nie, Xiaoyu
    Gupte-Singh, Komal
    Ritter, Timothy E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S340 - S340
  • [8] Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies
    Sands, Bruce E.
    D'Haens, Geert
    Panaccione, Remo
    Regueiro, Miguel
    Ghosh, Subrata
    Hudesman, David
    Ahmad, Harris A.
    Mehra, Dimpy
    Wu, Hsiuanlin
    Jain, Anjali
    Petersen, AnnKatrin
    Osterman, Mark T.
    Afzali, Anita
    Danese, Silvio
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (10) : 2084 - 2095
  • [9] Colitis ulcerosa: Vedolizumab as First-line Therapy?
    Franke, Katharina
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2017, 55 (06): : 531 - 531
  • [10] Confocal Laser Endomicroscopy to predict the efficacy of vedolizumab as first-line biotherapy in ulcerative colitis
    Queneherve, L.
    Trang-Poisson, C.
    Fantou, A.
    Flamant, M.
    Durand, T.
    Bouguen, G.
    Bregeon, J.
    Oullier, T.
    Amil, M.
    Dewitte, M.
    Bardot, S.
    Braudeau, C.
    Josien, R.
    Neunlist, M.
    Bourreille, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 460 - 460
12345